molybdenum has been researched along with Cancer of Endometrium in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Han, A; Kim, KK; Lokich, E; Moore, RG; Ribeiro, JR; Singh, RK; Yano, N | 1 |
Brard, L; Kawar, NM; Kim, KK; Lange, TS; Moore, RG; Singh, RK | 1 |
2 other study(ies) available for molybdenum and Cancer of Endometrium
Article | Year |
---|---|
Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; ErbB Receptors; Female; Humans; MAP Kinase Signaling System; Molybdenum; Phosphorylation; Protein Processing, Post-Translational; Proteolysis; Superoxide Dismutase; Superoxide Dismutase-1 | 2015 |
Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Enzyme Activation; Female; Humans; MAP Kinase Kinase 4; MAP Kinase Signaling System; Molybdenum; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species | 2011 |